Sharon Shacham
2018
In 2018, Sharon Shacham earned a total compensation of $2.1M as President and Chief Scientific Officer at Karyopharm Therapeutics, a 16% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $183,063 |
---|---|
Option Awards | $1,444,660 |
Salary | $450,000 |
Other | $11,660 |
Total | $2,089,383 |
Shacham received $1.4M in option awards, accounting for 69% of the total pay in 2018.
Shacham also received $183.1K in non-equity incentive plan, $450K in salary and $11.7K in other compensation.
Rankings
In 2018, Sharon Shacham's compensation ranked 5,502nd out of 14,244 executives tracked by ExecPay. In other words, Shacham earned more than 61.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 5,502 out of 14,244 | 61st |
Division Manufacturing | 2,077 out of 5,765 | 64th |
Major group Chemicals And Allied Products | 766 out of 2,128 | 64th |
Industry group Drugs | 641 out of 1,817 | 65th |
Industry Pharmaceutical Preparations | 494 out of 1,391 | 65th |
Source: SEC filing on April 19, 2019.
Shacham's colleagues
We found four more compensation records of executives who worked with Sharon Shacham at Karyopharm Therapeutics in 2018.
News
Karyopharm Therapeutics CEO Richard Paulson receives $8.4M in 2021
April 8, 2022
Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
April 7, 2021
Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
April 9, 2020
Karyopharm Therapeutics Executive Vice President, Chief Commercial Officer Anand Varadan receives $2.3M in 2018
April 19, 2019